Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Animal Insulin Market by Product (Porcine Insulin, Bovine Insulin) and by Application (Human, Animals): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12463

Pages: NA

Charts: NA

Tables: NA

Animal Insulin Market Outlook 2030:

Animal insulin is a derivative of pigs and cows. Animal insulin was the primary sort of insulin to be regulated to control diabetes. Until the 1980s, creature insulin was the lone treatment for insulin subordinate diabetes. Animal insulin is available in three different types of actions and durations, short acting, intermediate acting, and long acting. Short acting insulin consists of porcine neutral and hypurin bovine neutral. Subsequently, intermediate acting consists of hypurin porcine isophane and hypurin bovine isophane. Lastly, long acting insulin consists of bovine lente and porcine lente. Short and intermediate insulins act quickly on the body while long acting insulin takes time to act post injecting. With the plethora of advantages, there are reports to suggest that animal insulin can at times cause lethargy, short term illness, behavioral changes, nausea, and vomiting.

COVID-19 Impact Analysis

The coronavirus pandemic has a huge impact on businesses and has already caused an unprecedented collapse of economic activities. The COVID-19 impact is straining the healthcare systems globally.

The COVID-19 cases are increasing due to direct or indirect contact between humans. There has been no evidence or confirmation that animals can spread COVID-19 to humans. The myth that animals can spread the virus to humans has increased the number of abandoned pets. Furthermore, COVID-19 has weakened the supply chain and has created shortage of animal health products such as nutritional feed as well as vaccines globally. The animal health industry has been impacted largely, as many manufacturers in the animal health industry are left with a significantly reduced workforce. In addition, implementation of stringent government policies such as restrictions of import of raw materials from China is expected to hamper the growth of the animal health market.

Healthcare facilities are stocking up the animal-related health products, considering the high demand. This is expected to further create financial strain on the market due to procurement inefficiencies and wasted speeding. Due to the pandemic situation, many hospitals and veterinary clinics are overstocking the products.

Top Impacting Factors

  • Insulin assists with denying amyloid stores from the amyloid polypeptide islet from creating amongst cats. Consequently, insulin is without a doubt the best solution for the control of diabetes in canine and cat thus prompting heavy growth across regions.
  • Animal insulin market is further anticipated to grow due to increase in diabetic patients and rise in examination exercises in the district and arrangement of different makers. The growing geriatric populace along with rising prevalence of diabetes among the populace and rising mindfulness among individuals with respect to the advantages of insulin contribute toward the animal insulin market growth.
  • A detriment of animal insulin is in the pinnacle movement time. The pinnacle movement period for short-acting insulin happens up to 3 to 4 hours in the wake of infusing, which can make timing of dinners comparable to infusions more troublesome than with human and especially simple insulin.

Key Market Trends

  • Insulin assists with denying amyloid stores from the amyloid polypeptide islet from creating amongst cats. Consequently, insulin is without a doubt the ideal solution for the control of diabetes.
  • Vetsulin/Caninsulin is porcine Lente insulin supported for use in the two cats and dogs. Vetsulin, ProZinc, and Caninsulin are authoritatively enrolled for veterinary use. Subordinate of ProZinc is protamine zinc insulin (PZI), which is endorsed to be utilized in cats and can be utilized in the administration of diabetic canines.
  • Insulin decreases blood glucose levels by expanding fringe utilization of glucose and by smothering the creation of hepatic glucose. Insulin treatment for diabetic cat and dog is the establishment of the consideration and numerous kinds of insulin were demonstrated to be productive.

Key Benefits of the Report

  • This study presents the analytical depiction of the animal insulin market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the animal insulin market share.
  • The current market is quantitatively analyzed to highlight the market scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Animal Insulin Market Report

  • Which are the leading players active in the animal insulin market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the animal insulin market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is animal insulin market?
  • What is the animal insulin market prediction in the future?
  • What are the current trends and predicted trends?

Key Market Segments

  • By Product
    • Porcine Insulin
    • Bovine Insulin
  • By Application
    • Human
    • Animals
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Wockhardt UK
  • MannKind Corporation
  • Merck
  • Ganlee
  • BOEHRINGER INGELHEIM
  • Eli Lilly
  • Tonghua Dongbao
  • Novo Nordisk
  • Sanofi-Aventis
  • Zhuhai United Laboratories Co., Ltd.
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ANIMAL INSULIN MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Porcine Insulin

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Bovine Insulin

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: ANIMAL INSULIN MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Human

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Animals

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: ANIMAL INSULIN MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Animal Insulin Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Application
      • 6.2.6. Canada Animal Insulin Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Application
      • 6.2.7. Mexico Animal Insulin Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Application
    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Animal Insulin Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Application
      • 6.3.6. Germany Animal Insulin Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Application
      • 6.3.7. Italy Animal Insulin Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Application
      • 6.3.8. Spain Animal Insulin Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Application
      • 6.3.9. UK Animal Insulin Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Application
      • 6.3.10. Russia Animal Insulin Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Application
      • 6.3.11. Rest Of Europe Animal Insulin Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Application
    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Animal Insulin Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Application
      • 6.4.6. Japan Animal Insulin Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Application
      • 6.4.7. India Animal Insulin Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Application
      • 6.4.8. South Korea Animal Insulin Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Application
      • 6.4.9. Australia Animal Insulin Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Application
      • 6.4.10. Thailand Animal Insulin Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Application
      • 6.4.11. Malaysia Animal Insulin Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Application
      • 6.4.12. Indonesia Animal Insulin Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Application
      • 6.4.13. Rest of Asia Pacific Animal Insulin Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Application
    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Animal Insulin Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Application
      • 6.5.6. South Africa Animal Insulin Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Application
      • 6.5.7. Saudi Arabia Animal Insulin Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Application
      • 6.5.8. UAE Animal Insulin Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Application
      • 6.5.9. Argentina Animal Insulin Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Application
      • 6.5.10. Rest of LAMEA Animal Insulin Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Application
  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Eli Lilly

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novo Nordisk

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Sanofi-Aventis

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Tonghua Dongbao

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Ganlee

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Merck

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Wockhardt UK

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. MannKind Corporation

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. BOEHRINGER INGELHEIM

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Zhuhai United Laboratories Co., Ltd.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL INSULIN MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ANIMAL INSULIN MARKET FOR PORCINE INSULIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ANIMAL INSULIN MARKET FOR BOVINE INSULIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ANIMAL INSULIN MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ANIMAL INSULIN MARKET FOR HUMAN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ANIMAL INSULIN MARKET FOR ANIMALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ANIMAL INSULIN MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. NORTH AMERICA ANIMAL INSULIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. NORTH AMERICA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 11. U.S. ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 12. U.S. ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 13. CANADA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 14. CANADA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 15. MEXICO ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 16. MEXICO ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 17. EUROPE ANIMAL INSULIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. EUROPE ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 20. FRANCE ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 21. FRANCE ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. GERMANY ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 23. GERMANY ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. ITALY ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. ITALY ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. SPAIN ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 27. SPAIN ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. UK ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 29. UK ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. RUSSIA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. RUSSIA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. REST OF EUROPE ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 33. REST OF EUROPE ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. ASIA-PACIFIC ANIMAL INSULIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 35. ASIA-PACIFIC ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 37. CHINA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 38. CHINA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. JAPAN ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 40. JAPAN ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. INDIA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 42. INDIA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. SOUTH KOREA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. SOUTH KOREA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. AUSTRALIA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 46. AUSTRALIA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. THAILAND ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 48. THAILAND ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 49. MALAYSIA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. MALAYSIA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. INDONESIA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. INDONESIA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. REST OF ASIA PACIFIC ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. LAMEA ANIMAL INSULIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 56. LAMEA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 58. BRAZIL ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 59. BRAZIL ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. SOUTH AFRICA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 61. SOUTH AFRICA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. SAUDI ARABIA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. SAUDI ARABIA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. UAE ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 65. UAE ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. ARGENTINA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 67. ARGENTINA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. REST OF LAMEA ANIMAL INSULIN, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. REST OF LAMEA ANIMAL INSULIN, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. ELI LILLY: KEY EXECUTIVES
  • TABLE 71. ELI LILLY: COMPANY SNAPSHOT
  • TABLE 72. ELI LILLY: OPERATING SEGMENTS
  • TABLE 73. ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 74. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. NOVO NORDISK: KEY EXECUTIVES
  • TABLE 76. NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 77. NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 78. NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 79. NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. SANOFI-AVENTIS: KEY EXECUTIVES
  • TABLE 81. SANOFI-AVENTIS: COMPANY SNAPSHOT
  • TABLE 82. SANOFI-AVENTIS: OPERATING SEGMENTS
  • TABLE 83. SANOFI-AVENTIS: PRODUCT PORTFOLIO
  • TABLE 84. SANOFI-AVENTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. TONGHUA DONGBAO: KEY EXECUTIVES
  • TABLE 86. TONGHUA DONGBAO: COMPANY SNAPSHOT
  • TABLE 87. TONGHUA DONGBAO: OPERATING SEGMENTS
  • TABLE 88. TONGHUA DONGBAO: PRODUCT PORTFOLIO
  • TABLE 89. TONGHUA DONGBAO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. GANLEE: KEY EXECUTIVES
  • TABLE 91. GANLEE: COMPANY SNAPSHOT
  • TABLE 92. GANLEE: OPERATING SEGMENTS
  • TABLE 93. GANLEE: PRODUCT PORTFOLIO
  • TABLE 94. GANLEE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. MERCK: KEY EXECUTIVES
  • TABLE 96. MERCK: COMPANY SNAPSHOT
  • TABLE 97. MERCK: OPERATING SEGMENTS
  • TABLE 98. MERCK: PRODUCT PORTFOLIO
  • TABLE 99. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. WOCKHARDT UK: KEY EXECUTIVES
  • TABLE 101. WOCKHARDT UK: COMPANY SNAPSHOT
  • TABLE 102. WOCKHARDT UK: OPERATING SEGMENTS
  • TABLE 103. WOCKHARDT UK: PRODUCT PORTFOLIO
  • TABLE 104. WOCKHARDT UK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. MANNKIND CORPORATION: KEY EXECUTIVES
  • TABLE 106. MANNKIND CORPORATION: COMPANY SNAPSHOT
  • TABLE 107. MANNKIND CORPORATION: OPERATING SEGMENTS
  • TABLE 108. MANNKIND CORPORATION: PRODUCT PORTFOLIO
  • TABLE 109. MANNKIND CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. BOEHRINGER INGELHEIM: KEY EXECUTIVES
  • TABLE 111. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 112. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
  • TABLE 113. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
  • TABLE 114. BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. ZHUHAI UNITED LABORATORIES CO., LTD.: KEY EXECUTIVES
  • TABLE 116. ZHUHAI UNITED LABORATORIES CO., LTD.: COMPANY SNAPSHOT
  • TABLE 117. ZHUHAI UNITED LABORATORIES CO., LTD.: OPERATING SEGMENTS
  • TABLE 118. ZHUHAI UNITED LABORATORIES CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 119. ZHUHAI UNITED LABORATORIES CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL INSULIN MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ANIMAL INSULIN MARKET
  • FIGURE 3. SEGMENTATION ANIMAL INSULIN MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ANIMAL INSULIN MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANIMAL INSULIN MARKET
  • FIGURE 11. ANIMAL INSULIN MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. ANIMAL INSULIN MARKET FOR PORCINE INSULIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ANIMAL INSULIN MARKET FOR BOVINE INSULIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ANIMAL INSULIN MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. ANIMAL INSULIN MARKET FOR HUMAN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ANIMAL INSULIN MARKET FOR ANIMALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 21. COMPETITIVE DASHBOARD
  • FIGURE 22. COMPETITIVE HEATMAP: ANIMAL INSULIN MARKET
  • FIGURE 23. TOP PLAYER POSITIONING, 2024
  • FIGURE 24. ELI LILLY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 25. ELI LILLY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 26. ELI LILLY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 27. NOVO NORDISK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. NOVO NORDISK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. SANOFI-AVENTIS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. SANOFI-AVENTIS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. SANOFI-AVENTIS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. TONGHUA DONGBAO: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. TONGHUA DONGBAO: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. TONGHUA DONGBAO: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. GANLEE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. GANLEE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. GANLEE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. MERCK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. MERCK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. MERCK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. WOCKHARDT UK: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. WOCKHARDT UK: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. WOCKHARDT UK: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. MANNKIND CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. MANNKIND CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. MANNKIND CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. BOEHRINGER INGELHEIM: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. ZHUHAI UNITED LABORATORIES CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. ZHUHAI UNITED LABORATORIES CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. ZHUHAI UNITED LABORATORIES CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Animal Insulin Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue